Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Efficacy of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis: Randomized Double-blind Placebo-controlled Trial
Brief Summary: The investigators propose to study the efficacy of adalimumab versus placebo (double-blind randomization on inclusion into 2 equal groups) on reduction of ocular inflammation quantified by laser flare photometry after two months of treatment in patients with active uveitis despite well conducted treatment with steroid eye drops and MTX. The primary objective is to demonstrate a higher response rate at 2 months in the adalimumab arm versus the placebo arm. Will be considered as responding patients those in whom the evaluated eye, 2 months after inclusion, presents at least 30% reduction of inflammation on laser flare photometry and improvement or a stable appearance on slit lamp examination. After the second month, all patients wishing to continue the trial and presenting a satisfactory clinical state will be treated with adalimumab for a total of one year after inclusion to descriptively evaluate the efficacy and safety of treatment over 10 to 12 months.


Options:
A: Arm Label: adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Anti-tumor necrosis factor alpha monoclonal antibody | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Anti-tumor necrosis factor alpha monoclonal antibody; Assigned to Arm(s): adalimumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Double-Blind Adalimumab + MTX; Type: EXPERIMENTAL; Interventions: Biological: Double-Blind Adalimumab/Placebo + MTX | Arm Label: Double-Blind Placebo + MTX; Type: PLACEBO_COMPARATOR; Interventions: Biological: Double-Blind Adalimumab/Placebo + MTX | Arm Label: Double-Blind Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Double-Blind Adalimumab/Placebo | Arm Label: Double-Blind Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Double-Blind Adalimumab/Placebo | Arm Label: OLE BSA Adalimumab + MTX; Type: EXPERIMENTAL; Interventions: Drug: OLE BSA Adalimumab +/- MTX | Arm Label: OLE BSA Adalimumab; Type: EXPERIMENTAL; Interventions: Drug: OLE BSA Adalimumab +/- MTX | Arm Label: OLE FD Adalimumab + MTX; Type: EXPERIMENTAL; Interventions: Drug: OLE FD Adalimumab +/- MTX | Arm Label: OLE FD Adalimumab; Type: EXPERIMENTAL; Interventions: Drug: OLE FD Adalimumab +/- MTX | Intervention Type: BIOLOGICAL; Name: Double-Blind Adalimumab/Placebo + MTX; Assigned to Arm(s): Double-Blind Adalimumab + MTX, Double-Blind Placebo + MTX | Intervention Type: BIOLOGICAL; Name: Double-Blind Adalimumab/Placebo; Assigned to Arm(s): Double-Blind Adalimumab, Double-Blind Placebo | Intervention Type: DRUG; Name: OLE BSA Adalimumab +/- MTX; Assigned to Arm(s): OLE BSA Adalimumab, OLE BSA Adalimumab + MTX | Intervention Type: DRUG; Name: OLE FD Adalimumab +/- MTX; Assigned to Arm(s): OLE FD Adalimumab, OLE FD Adalimumab + MTX
C: Arm Label: CNTO 148 (Golimumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO 148 (Golimumab), Drug: Methotrexate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: CNTO 148 (Golimumab); Assigned to Arm(s): CNTO 148 (Golimumab) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): CNTO 148 (Golimumab), Placebo
D: Arm Label: Infliximab plus Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Infliximab plus methotrexate | Arm Label: Combination of DMARDs; Type: EXPERIMENTAL; Interventions: Drug: Combination of DMARDs | Arm Label: Methotrexate alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate alone | Intervention Type: DRUG; Name: Infliximab plus methotrexate; Assigned to Arm(s): Infliximab plus Methotrexate | Intervention Type: DRUG; Name: Combination of DMARDs; Assigned to Arm(s): Combination of DMARDs | Intervention Type: DRUG; Name: Methotrexate alone; Assigned to Arm(s): Methotrexate alone

Answer: A